The US Supreme Court's recent decision in Association for Molecular Pathology v. Myriad
Genetics, Inc. declared, for the first time, that isolated human genes cannot be patented …

Cancer is a leading cause of morbidity and mortality worldwide. Each year, millions of
people worldwide are diagnosed with cancer, and more than half of them die. Various …

Contemporary law has become grounded in the conviction that not only the outputs of
innovation-artistic expressions, scientific methods, and technological advances-but also the …

For decades, Fourth Amendment protections have turned on" reasonable expectations of
privacy." But a new era may be dawning. There is growing interest among judges and …

Antibodies constitute a staggering $145 billion annual market-an amount projected to almost
double by 2026. Consequently, patents covering antibodies are among the most valuable in …

Patent law-and in particular the law governing patent eligibility-is in a state of crisis. This
crisis is one of profound confusion. Confusion exists because the current approach to …

In the past decade, the US patent system has been transformed. Before Congress passed
the America Invents Act (AIA) in 2011, the validity of issued patents was decided almost …

Clinical research faces a reproducibility crisis. Many recent clinical and preclinical studies
appear to be irreproducible-their results cannot be verified by outside researchers. This is …

Often what is not said is as significant as what is said. In its recent Myriad Genetics decision,
the United States Supreme Court is curiously silent about the relationship between its …

In a series of recent cases, the US Supreme Court has made clear that there are substantial
constraints on the categories of actions and materials for which patent protection may be …